Inceptive
Inceptive (Inceptive Nucleics, Inc.) builds AI foundation models trained on heterogeneous biological data and validated by an in-house wet lab to design sequence-based therapeutics — mRNA, siRNA, ASOs, and peptides — for large pharmaceutical and biotechnology partners under licensing and milestone-based collaboration agreements.
- Company typePrivate
- Founded2021
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Inceptive does
Inceptive (legal entity: Inceptive Nucleics, Inc.) is a private AI biotech founded in 2021 and headquartered in Palo Alto, California, with additional offices in Berlin and Zurich. The company builds end-to-end foundation models trained on heterogeneous, multi-scale biological data spanning sequence, function, and structure, with a focus on designing sequence-based therapeutics including mRNA, siRNA, antisense oligonucleotides (ASOs), and peptides. A defining architectural element is the tight loop between in-silico model training and an in-house wet laboratory that validates designs in vitro and in vivo at high frequency, shortening the path from computational design to drug candidate. Proprietary algorithms are engineered to extrapolate beyond the best molecules in the training data, iteratively proposing designs superior to anything previously observed.
The company serves large pharmaceutical and biotechnology companies through a direct strategic-partnership model rather than a self-serve or SaaS offering. Partnerships involve customizing foundation models against partner-specific data, co-designing novel therapeutic candidates, and transferring knowledge so that partners can advance candidates to the clinic. Revenue derives from upfront licensing payments and milestone payments tied to preclinical, regulatory, and commercial achievements. The flagship disclosed commercial deal is a three-year collaboration with Alnylam Pharmaceuticals announced in June 2026, valued at up to $2 billion with a $30 million upfront payment in cash and equity, targeting RNAi therapeutic discovery.
Inceptive is backed by Andreessen Horowitz (a16z), NVIDIA, S32, and Obvious Ventures, and has raised approximately $120 million across two disclosed funding rounds (a Series A of roughly $20 million in 2022 and a $100 million round in September 2023 co-led by a16z and NVIDIA). Leadership is anchored by CEO Jakob Uszkoreit, co-inventor of the Transformer architecture and former Google Brain researcher. As of the latest data, the company has 11–50 employees (approximately 28 visible in team photos), is privately held with no public ticker, and has not disclosed revenue figures.
Inceptive firmographics
Firmographics- Name
- Inceptive
- Legal name
- Inceptive Nucleics, Inc.
- Website
- https://inceptive.life
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inceptive (Inceptive Nucleics, Inc.) builds AI foundation models trained on heterogeneous biological data and validated by an in-house wet lab to design sequence-based therapeutics — mRNA, siRNA, ASOs, and peptides — for large pharmaceutical and biotechnology partners under licensing and milestone-based collaboration agreements.
- Ownership category
- akta.pro rank
Inceptive industry classification
Industry- Product category
- AI-Driven Biopharmaceutical R&D
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)
Keywords
Where Inceptive is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Inceptive business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Strategic Partnership Licensing: Licensing AI foundation models to pharmaceutical partners with upfront payments, followed by milestone payments tied to preclinical, regulatory, and commercial achievements. Total deal value can reach up to $2 billion for flagship partnerships.
- Co-development Agreements: Working with partners to co-design novel medicines and transfer knowledge, empowering partners to take candidates to clinic. Revenue derived from collaborative research payments and development milestones.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Inceptive product offering
Product offeringCore offering
Inceptive designs RNA-based therapeutics using AI foundation models trained on heterogeneous biological data (sequence, function, and structure), specializing in mRNA, siRNA, ASOs, and peptides. The company pairs these foundation models with an in-house wet lab that validates designs in vitro and in vivo, enabling rapid iterative design-to-candidate cycles. It monetizes this capability by partnering with pharmaceutical and biotechnology companies to customize foundation models and co-design novel medicines.
Product overview
Inceptive offers a unified AI-powered drug discovery platform consisting of foundation models trained on biological data and an in-house wet lab for validation. The platform specializes in sequence-based medicines (mRNA, siRNA, ASOs, peptides) and combines deep learning models with experimental validation to design novel therapeutic candidates. The company also provides partnership services to customize foundation models for specific drug discovery programs.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Foundation Models for Drug Discovery End-to-end foundation models that learn to design molecules directly from diverse observations of life, specializing in sequence-based medicines (mRNA, siRNA, ASOs, peptides). Models train on public datasets, in-house experimental data, and partner data, and are engineered to extrapolate beyond the best molecules in training data. Licensed to pharmaceutical and biotechnology partners for use in their discovery programs.
- Custom Foundation Model Partnerships Custom foundation models built in collaboration with pharmaceutical and biotechnology partners for their specific discovery programs. Includes joint co-design of novel medicines, tuning of models on partner data, and knowledge transfer so partners can advance candidates to the clinic. Delivered via strategic collaborations with upfront payments and milestone-based compensation tied to preclinical, regulatory, and commercial outcomes.
Quantifiable outcome
- Reduced discovery timelines through AI-powered siRNA design
- +1 more outcomes
Companies that use Inceptive
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Inceptive technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Inceptive partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Alnylam PharmaceuticalsflagshipThree-year strategic collaboration worth up to $2 billion to accelerate RNAi therapeutics discovery. Inceptive provides AI foundation models; Alnylam contributes 20+ years of proprietary siRNA data and RNAi platform expertise. Deal includes $30 million upfront with additional preclinical, regulatory, and commercial milestone payments. Aims to enhance siRNA design and support Alnylam's 2030 pipeline expansion strategy.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Inceptive competitors and assessment
Company assessmentDirect peers
- Generate:Biomedicines: AI foundation-model platform for protein and sequence-based therapeutic design. Closely analogous in framing ('generative biology' foundation models) and modality span to Inceptive.
- Insilico Medicine: AI-driven drug discovery platform combining generative chemistry, target identification, and preclinical development. Comparable in offering end-to-end AI drug discovery with strategic pharma partnerships.
- Isomorphic Labs: Alphabet/DeepMind-founded AI drug discovery company building foundation models for therapeutic design. Most direct competitor in the AI foundation-models-for-biology category, with overlapping modality ambitions and partner-based GTM.
- Atomwise: AI small-molecule discovery company with pharma partnerships. Comparable as an AI-first drug discovery platform with enterprise partnership GTM, though more structure-based and small-molecule focused.
Emerging players
- EvolutionaryScale: Frontier AI research company building large models for biology. Closely parallels Inceptive's foundation-model framing of biology, though more research-stage and modality-agnostic.
- Cradle Bio: AI platform for protein design and engineering with a wet-lab loop. Comparable in combining generative AI with experimental validation, though more focused on proteins rather than RNA.
- Profluent Bio: AI foundation models for protein engineering and sequence design, founded by AI researchers. Comparable in technical thesis (deep learning from life / biology foundation models) though initially protein-focused.
Broad incumbents
- DeepMind (Google): Parent organization of Isomorphic Labs and developer of AlphaFold. Relevant as the broad incumbent whose biology AI efforts (and spinoff) most directly compete with Inceptive's foundation-model approach.
- Recursion Pharmaceuticals: Publicly listed AI drug discovery company combining high-throughput wet-lab experimentation with ML. Compares as a larger, established player in the AI-bio space with internal pipeline plus partnerships.
Others
- Alnylam Pharmaceuticals: Flagship strategic partner and dominant siRNA therapeutics company. Listed as 'others' because it is currently a customer/partner rather than a competitor, but it operates in the same RNA therapeutics category and represents the most validated end-market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Inceptive social profiles
Digital presenceInceptive financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inceptive leadership team
Management profileNumber of profiles
Profiles1 record
Inceptive funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inceptive M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inceptive
What does Inceptive do?
Inceptive designs RNA-based therapeutics using AI foundation models trained on heterogeneous biological data (sequence, function, and structure), specializing in mRNA, siRNA, ASOs, and peptides. The company pairs these foundation models with an in-house wet lab that validates designs in vitro and in vivo, enabling rapid iterative design-to-candidate cycles. It monetizes this capability by partnering with pharmaceutical and biotechnology companies to customize foundation models and co-design novel medicines.
Is Inceptive a public or private company?
Inceptive is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inceptive founded?
Inceptive was founded in 2021. It employs 11 to 50 people.
Where is Inceptive based?
Inceptive is headquartered in Palo Alto, United States, in the North America region.
How does Inceptive make money?
Two revenue lines are on record. Strategic Partnership Licensing is the primary driver. The others are co-development Agreements.
Who are Inceptive's main competitors?
Direct peers on record are Generate:Biomedicines, Insilico Medicine, Isomorphic Labs and Atomwise. Emerging players are EvolutionaryScale, Cradle Bio and Profluent Bio. Broad incumbents are DeepMind (Google) and Recursion Pharmaceuticals. Alnylam Pharmaceuticals is listed as an others.
Does Inceptive have an API?
No public API is recorded for Inceptive.
What industry is Inceptive in?
Inceptive's product category is AI-Driven Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.